CANSINOBIO (06185) has announced that its recombinant trivalent poliomyelitis vaccine, utilizing Sf-RVN cells, has obtained approval from China's National Medical Products Administration to initiate clinical trials. This vaccine, crafted through sophisticated protein structure design and virus-like particle (VLP) assembly technology, eliminates viral genetic material entirely and operates independently of live viruses during both production and testing phases. Such features are anticipated to deliver exceptional safety and robust immunogenicity. Notably, the non-infectious VLP-based polio vaccine stands endorsed by the World Health Organization as a premier choice for future polio eradication efforts, positioning it as a potentially ideal solution for the disease's global elimination.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。